Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Localised prostate cancer, intermediate risk, drawn from the whole corpus: 6 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether favourable intermediate risk can be safely watched in the long term.
How to select men for hormone therapy without giving it to everyone in the unfavourable group.
Cribriform and intraductal patterns are prognostic but not yet in the risk groups.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
5-year biochemical or clinical failure-free 95.
A milestone in how this cancer is treated.
5-year failure-free survival 84% in both arms, non-inferior.
A milestone in how this cancer is treated.